Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-Human VEGFA Nanobody (SAA0902)

Catalog #:   RHD12603 Specific References (16) DATASHEET
Host species: Alpaca
Isotype: VHH-8His-Cys-tag
Applications: ELISA
Expression system: Mammalian Cells
Overview

Catalog No.

RHD12603

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Alpaca

Isotype

VHH-8His-Cys-tag

Clonality

Monoclonal

Target

Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A

Concentration

0.32 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Purified by Nickel column.

Accession

P15692

Applications

ELISA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA0902

Data Image
  • SDS-PAGE
    SDS PAGE for Human VEGFA Nanobody
References

Radiotherapy-derived engineered stem cell exosomes improve anti-glioma immunotherapy by promoting the formation of tertiary lymphoid structure and improve the release of type I interferon., PMID:40121481

Comprehensive biomarker and modeling approach to support dose finding for BI 836880, a VEGF/Ang-2 inhibitor., PMID:39402675

Antibody fragments targeting the extracellular domain of follicular stimulating hormone receptor for contraception in male dogs and cats., PMID:38875921

Impaired Testicular Function without Altering Testosterone Concentration Using an Anti-Follicular-Stimulating Hormone Receptor (Anti-FSHr) Single-Chain Variable Fragment (scFv) in Long-Tailed Macaques (Macaca fascicularis)., PMID:37508065

Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition., PMID:36241203

A Structural Overview of Vascular Endothelial Growth Factors Pharmacological Ligands: From Macromolecules to Designed Peptidomimetics., PMID:34833851

VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo., PMID:33830713

Nintedanib and a bi-specific anti-VEGF/Ang2 nanobody selectively prevent brain metastases of lung adenocarcinoma cells., PMID:32918638

Oligoclonal selection of nanobodies targeting vascular endothelial growth factor., PMID:30409071

Intraocular Penetration of a vNAR: In Vivo and In Vitro VEGF165 Neutralization., PMID:29614715

Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate., PMID:29035637

Development of a novel nano-sized anti-VEGFA nanobody with enhanced physicochemical and pharmacokinetic properties., PMID:28841807

Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody., PMID:25645505

A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment., PMID:24569074

The untapped potential of Gallium 68-PET: the next wave of ⁶⁸Ga-agents., PMID:23232184

Nanoantibodies for detection and blocking of bioactivity of human vascular endothelial growth factor A(165)., PMID:22817466

Datasheet
$ 372
Product specifications
100 μg 372 1 mg 1860

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human VEGFA Nanobody (SAA0902) [RHD12603]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only